Share This Page
Drug Price Trends for NDC 00013-2646
✉ Email this page to a colleague
Average Pharmacy Cost for 00013-2646
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GENOTROPIN 12 MG CARTRIDGE | 00013-2646-81 | 1715.72667 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00013-2646
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
00013-2646 Market Analysis and Financial Projection
Market Analysis and Price Projections for Genotropin (NDC: 00013-2646)
Introduction
Genotropin, a somatropin product manufactured by Pfizer, is a crucial medication for treating growth hormone deficiency (GHD) and other growth-related disorders. This analysis will delve into the market dynamics, pricing, and future projections for Genotropin, particularly focusing on the NDC code 00013-2646.
Market Overview
Genotropin is part of a competitive market for growth hormone therapies, which includes other brands like Norditropin, Humatrope, and Nutropin. The market is characterized by high demand, especially for pediatric and adult GHD patients, as well as those with conditions such as Turner syndrome, Prader-Willi syndrome, and chronic renal failure[3].
Pricing and Cost Considerations
The pricing of Genotropin is influenced by several factors, including the dosage form, patient weight, and treatment duration. Here are some key points:
- Dosage and Pricing: Genotropin is available in various dosages, including 5 mg and 12 mg cartridges. The recommended dosage varies from 0.16 mg/kg to 0.30 mg/kg per week, leading to significant variations in annual costs. For example, the annual cost for a patient weighing 19.30 kg can range from $4,584 to $14,709, depending on the dosage and brand[3].
- Comparison with Other Brands: Somatrogon, a newer biosimilar, is more expensive than some somatropin options, including Genotropin. However, Genotropin remains a cost-effective option due to its lower list price and widespread reimbursement by public drug plans[3].
Impact of Drug Price Negotiations
The Medicare Drug Price Negotiation Program, introduced under the Inflation Reduction Act, is set to significantly impact the pricing of high-expenditure drugs, including those used for GHD. Here’s how it might affect Genotropin:
- Negotiated Prices: Although Genotropin is not listed among the initial 10 drugs selected for negotiation, future cycles of negotiations could include it. If negotiated prices are applied, they would likely reduce the out-of-pocket costs for Medicare beneficiaries and potentially influence market prices more broadly[2].
- Projected Savings: The program aims to save an estimated $6 billion in net covered prescription drug costs across the selected drugs in 2023. If Genotropin were to be included in future negotiations, similar savings could be anticipated, benefiting both patients and healthcare systems[2].
Drug Shortages and Availability
The availability of Genotropin is crucial for patient care. Here are some points regarding its current status:
- Current Availability: Unlike Norditropin, which is currently on shortage due to increased demand and manufacturing delays, Genotropin is available from Pfizer in various formulations, including cartridges and MiniQuick injections[5].
- Implications for Patient Care: The availability of Genotropin ensures that patients have a reliable treatment option, mitigating the risks associated with drug shortages and ensuring continuous care.
Pharmacoeconomic Considerations
Pharmacoeconomic analyses play a critical role in evaluating the cost-effectiveness of Genotropin:
- Cost-Effectiveness Analysis: Studies have compared the cost-effectiveness of Genotropin with other somatropin products. These analyses consider various forms of wastage, adherence, and the overall economic impact from the perspective of public healthcare payers. Genotropin often emerges as a cost-effective option due to its lower list price and equivalent efficacy[3].
- Wastage and Adherence: The economic model for Genotropin includes considerations for different types of wastage (last-dose, device-setting, storage, and preparation) and adherence issues, which can significantly impact the overall cost-effectiveness of the treatment[3].
Future Price Projections
Several factors will influence the future pricing of Genotropin:
- Market Competition: The introduction of biosimilars and other somatropin products could lead to competitive pricing, potentially reducing the cost of Genotropin. However, Genotropin’s established market presence and reimbursement status are likely to maintain its market share[3].
- Regulatory Changes: The Medicare Drug Price Negotiation Program and other regulatory initiatives aimed at increasing transparency and controlling drug prices could lead to lower prices for Genotropin and similar drugs[2].
- Inflation and Economic Factors: The annual price updates for negotiated drugs under the Medicare program will be tied to the Consumer Price Index (CPI-U), ensuring that prices do not escalate disproportionately[2].
Key Takeaways
- Market Position: Genotropin remains a significant player in the growth hormone therapy market due to its widespread reimbursement and cost-effectiveness.
- Pricing Dynamics: The pricing of Genotropin is influenced by dosage, patient weight, and treatment duration, with potential future reductions through negotiated prices.
- Availability: Unlike some competitors, Genotropin is currently available, ensuring continuous patient care.
- Pharmacoeconomic Impact: Genotropin is generally cost-effective, especially when considering various forms of wastage and adherence.
FAQs
Q: What is the current dosage and pricing structure for Genotropin?
Genotropin is available in various dosages, including 5 mg and 12 mg cartridges, with recommended dosages ranging from 0.16 mg/kg to 0.30 mg/kg per week. The annual cost varies significantly based on these factors, ranging from $4,584 to $14,709 for a patient weighing 19.30 kg[3].
Q: How does the Medicare Drug Price Negotiation Program affect Genotropin pricing?
Although Genotropin is not currently included in the negotiation program, future cycles could include it, potentially reducing out-of-pocket costs for Medicare beneficiaries and influencing market prices[2].
Q: What are the implications of drug shortages on Genotropin availability?
Unlike Norditropin, which is on shortage, Genotropin is currently available from Pfizer, ensuring continuous patient care and mitigating the risks associated with drug shortages[5].
Q: How does Genotropin compare in terms of cost-effectiveness to other somatropin products?
Genotropin is generally cost-effective compared to other somatropin products, considering factors such as wastage, adherence, and overall economic impact from the perspective of public healthcare payers[3].
Q: What are the future price projections for Genotropin?
Future prices for Genotropin will be influenced by market competition, regulatory changes, and economic factors such as inflation. The introduction of biosimilars and negotiated prices could lead to competitive pricing and potential reductions[2][3].
Sources
- DailyMed: GENOTROPIN- somatropin kit - DailyMed
- CMS: Negotiated Prices for Initial Price Applicability Year 2026 - CMS
- NCBI Bookshelf: Pharmacoeconomic Review - Somatrogon (Ngenla) - NCBI Bookshelf
- Oregon Drug Price Transparency Program: Prescription Drug Price Transparency Results and Recommendations
- ASHP: Drug Shortage Detail: Somatropin Injection - ASHP
More… ↓
